Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

Stopped The decision to suspend this study was based upon evaluation of pandemic-related challenges impacting both clinical trial sites and potential participants. This suspension was initiated prior to site activation and participant recruitment.

Conditions

• Post-Traumatic Stress Disorder

Interventions

• DRUG: Nabiximols
• DRUG: Placebo

Sponsor

Jazz Pharmaceuticals